Intracerebral Hemorrhage
Conditions
Brief summary
As one of the most serious forms of acute stroke, the early mortality rate of intracerebral hemorrhage(ICH) can be as high as 30-40%. The incidence of intracerebral hemorrhage increases with the increase of age. Under the circumstance of the aggravation of aging in China, intracerebral hemorrhage brings a certain burden to families and society. The results of several studies in recent years have failed to provide new therapeutic approaches for the treatment of cerebral hemorrhage. Therefore, novel therapeutic approaches is urgently needed for ICH. Primary and secondary prevention, acute inpatient care, and poststroke rehabilitation are all critical. The objective of this cohort study is to explore factors that might influence the long-term prognosis of patients with ICH and to further identify new potential targets for intervention.
Detailed description
The observational cohort study will be used to find the possible treatment methods and predictors of functional outcome. The medical records of patients will be collected, including age, sex, comorbid conditions, toxic habits, use of medications (antiplatelets, anticoagulants, and antihypertensives), systolic and diastolic blood pressure, Glasgow Coma Scale (GCS) score, and National Institutes of Health Stroke Scale (NIHSS) score on admission. Image data will also be collected. Follow-up information will be obtained from the medical records or telephone interviews.
Interventions
Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
Sponsors
Study design
Eligibility
Inclusion criteria
* Primary intracerebral hemorrhage * Over 18 year-old
Exclusion criteria
* Secondary intracerebral hemorrhage, such as aneurysmal, hemorrhagic transformation of ischemic stroke, cavernomas, arterio-venous malformations, central venous thrombosis, trauma-related, or tumor. * Pregnant patients. * Any condition which, in the judgment of the investigator, might increase the risk to the patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional outcome | 90-day | evaluated by modified Rankin Scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neurological deterioration | 14-day | evaluated by NIHSS or GCS |
| Functional outcome | 1-year | evaluated by modified Rankin Scale |
| Cerebrovascular disease event | 2-year | ischemic and hemorrhagic events |
Countries
China